David I. Quinn - Keck Medicine of USC

Dr. David I. Quinn

Claim this profile

USC / Norris Comprehensive Cancer Center

Studies Prostate Cancer
Studies Bladder Cancer
8 reported clinical trials
19 drugs studied

Area of expertise

1Prostate Cancer
David I. Quinn has run 4 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
2Bladder Cancer
David I. Quinn has run 3 trials for Bladder Cancer. Some of their research focus areas include:
Stage IV
Stage III

Affiliated Hospitals

Image of trial facility.
USC / Norris Comprehensive Cancer Center
Image of trial facility.
Los Angeles County-USC Medical Center

Clinical Trials David I. Quinn is currently running

Image of trial facility.

Radium-223 + M3814 + Avelumab

for Prostate Cancer

This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as radium-223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to find out the better treatment between radium-223 dichloride alone, radium-223 dichloride in combination with M3814, or radium-223 dichloride in combination with both M3814 and avelumab, to lower the chance of prostate cancer growing or spreading in the bone, and if this approach is better or worse than the usual approach for advanced prostate cancer not responsive to hormonal therapy.
Recruiting1 award Phase 1 & 2
Image of trial facility.

Immunotherapy With or Without Surgery

for Kidney Cancer

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria

More about David I. Quinn

Clinical Trial Related12 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments David I. Quinn has experience with
  • Eribulin Mesylate
  • Avelumab
  • Controlled Low Calorie Diet
  • Short-term Fasting
  • Modified Fast
  • Fasting

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does David I. Quinn specialize in?
Is David I. Quinn currently recruiting for clinical trials?
Are there any treatments that David I. Quinn has studied deeply?
What is the best way to schedule an appointment with David I. Quinn?
What is the office address of David I. Quinn?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security